Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor

Mean Platelet Volume ◽

Kinase Inhibitor ◽

Progression Free Survival ◽

Platelet Volume ◽

Free Survival ◽

Lymphocyte To Monocyte Ratio ◽

470P Progression-free survival and response rate with EGFR tyrosine kinase inhibitor treatment according to EGFR mutation subtype in advanced lung adenocarcinoma

Annals of Oncology ◽

10.1093/annonc/mdw594.034 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Author(s):

C.S. Chai ◽

C.K. Liam ◽

Y.K. Pang ◽

K.S. Kow ◽

C.K. Wong ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Egfr Mutation ◽

Response Rate ◽

Kinase Inhibitor ◽

Progression Free Survival ◽

Free Survival ◽

Inhibitor Treatment

470P Progression-free survival and response rate with EGFR tyrosine kinase inhibitor treatment according to EGFR mutation subtype in advanced lung adenocarcinoma

Annals of Oncology ◽

10.1016/s0923-7534(21)00628-1 ◽

2016 ◽

Vol 27 ◽

pp. ix150-ix151

Author(s):

C.S. Chai ◽

C.K. Liam ◽

Y.K. Pang ◽

K.S. Kow ◽

C.K. Wong ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Egfr Mutation ◽

Response Rate ◽

Kinase Inhibitor ◽

Progression Free Survival ◽

Free Survival ◽

Inhibitor Treatment

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma

OncoTargets and Therapy ◽

10.2147/ott.s62639 ◽

2014 ◽

pp. 799 ◽

Cited By ~ 9

Author(s):

Jeng-Sen Tseng ◽

Tsung-Ying Yang ◽

Kun-Chieh Chen ◽

Kuo-Hsuan Hsu ◽

Chong-Jen Yu ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Egfr Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor Therapy ◽

Egfr-Tyrosine Kinase Inhibitor (Tki) Rechallenge with Bevacizumab in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc)

Annals of Oncology ◽

10.1093/annonc/mdu349.65 ◽

2014 ◽

Vol 25 ◽

pp. iv452

Author(s):

K. Otsuka ◽

A. Hata ◽

R. Kato ◽

J. Takeshita ◽

C. Okuda ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Small Cell ◽

Small Cell Lung ◽

P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.09.1514 ◽

2017 ◽

Vol 12 (11) ◽

pp. S2230

Author(s):

R. Rosell ◽

N. Karachaliou ◽

J.J. Cui ◽

I. Chaib ◽

J. Berenguer ◽

...

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Innate Resistance ◽

Egfr Tyrosine Kinase ◽

EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.08.015 ◽

2021 ◽

Vol 16 (11) ◽

pp. 1793-1797

Author(s):

Sophie Stock-Martineau ◽

Frances A. Shepherd

Keyword(s):

Tyrosine Kinase ◽

Kinase Inhibitor ◽

Line Treatment ◽

First Line ◽

Egfr Tyrosine Kinase ◽

Egfr Mutant ◽

First Line Treatment

Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival

Pathology - Research and Practice ◽

10.1016/j.prp.2018.01.010 ◽

2018 ◽

Vol 214 (3) ◽

pp. 335-342 ◽

Cited By ~ 4

Author(s):

Soon Auck Hong ◽

Si-Hyong Jang ◽

Mee-Hye Oh ◽

Sung Joon Kim ◽

Jin-Hyung Kang ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Poor Survival ◽

Tyrosine Kinase Inhibitor Therapy ◽

Abstract 1756: Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma

10.1158/1538-7445.am2014-1756 ◽

2014 ◽

Author(s):

Hui-Yi Shiao ◽

Tsu-An Hsu ◽

Wen-Hsing Lin ◽

Tsong-Toh Yang ◽

Hui-Fang Hsieh ◽

...

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase

Abstract 2609: Overexpression of YAP1 of EGFR-mutant lung adenocarcinoma before tyrosine kinase inhibitor is associated with poor survival

10.1158/1538-7445.am2018-2609 ◽

2018 ◽

Author(s):

Soon Auck Hong ◽

Jin-Hyoung Kang ◽

Sook Hee Hong

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Poor Survival ◽

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma

BMC Cancer ◽

10.1186/s12885-018-5116-9 ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 1

Author(s):

Eun Young Kim ◽

Arum Kim ◽

Gaeun Lee ◽

Hangsuck Lee ◽

Yoon Soo Chang

Keyword(s):

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase